Objective: To investigate the clinical characteristics and differential diagnosis of chronic myelomonocytic leukemia (CMML) accompanied with non-Hodgkin 's lymphoma (NHL). Methods: The clinical data, imaging findings, pathomorphological features and immunohistochemical markers of two patients with CMML accompanied with NHL were retrospectively analyzed, and related literatures were reviewed. Results: The 2 cases were elderly women presented with fatigue or symptoms of tumor invasion at corresponding sites. Case 1 was diagnosed with CMML and thereafter having NHL diagnosed, and case 2 was diagnosed with CMML and NHL simultaneously. Laboratory examination showed that peripheral white blood cells were increased,especially mononuclear cells, and lactate dehydrogenase was also increased. Bone marrow smears showed active proliferation with morbid hematopoiesis. On immunophenotyping, the bone marrow cells often expressed CD14+CD64+. Analysis of chromosome fluorescence in situ hybridization showed that BCR-ABL fusion gene were negative. PET/CT examination displayed that high metabolic lesions in bone marrow were not found in the 2 cases, but showed hypermetabolic small intestinal lesions in case 1 and lung lesions in case 2. SUVmax value were 12.60 and 6.72, respectively. Pathological examination suggested that these 2 patients were B-cell-derived NHL. Immunohistochemical study showed that LCA, CD20, CD79a, Bcl-6 and Ki-67 were positive, CD5, CD10, CD3, CylinD1, CD56, CD23 and CD21 were negative. Conclusions: CMML accompanied with NHL is rare and lacks specific clinical manifestation. With the laboratory findings combined with imaging, histopathology and immunohistochemical examination, the diagnostic accuracy could be improved.
LI Jiaming, ZHANG Sujiang, WANG Ying, YAN Zeying, LIU Zhiyin, SUN Haimin, CHEN Yubao, CHEN Yu, LUO Fangxiu, SUN Jing
. Chronic myelomonocytic leukemia accompanied with extranodal lymphoma : a clinical feature analysis[J]. Journal of Diagnostics Concepts & Practice, 2018
, 17(01)
: 76
-81
.
DOI: 10.16150/j.1671-2870.2018.01.014
[1] Arber DA, Orazi A, Hasserjian R, et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood,2016, 127(20):2391-2405.
[2] Itzykson R, Duchmann M, Lucas N, et al.CMML: Clinical and molecular aspects[J]. Int J Hematol,2017,105(6):711-719.
[3] Harada Y, Harada H. Rinsho Ketsueki.Chronic myelomonocytic leukemia(CMML): recent advances in molecular pathogenesis and treatment[J]. Rinsho Ketsueki,2016,57(2):147-155.
[4] Bacher U, Haferlach T, Schnittger S, et al.Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia[J]. Br J Haematol,2011,153(2):149-167.
[5] Such E, Germing U, Malcovati L, et al.Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia[J]. Blood,2013,121(15):3005-3015.
[6] Elena C, Gallì A, Such E, et al.Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia[J]. Blood,2016,128(10):1408-1417.
[7] Koss MN.Malignant and benign lymphoid lesions of the lung[J]. Ann Diagn Pathol,2004,8(3):167-187.
[8] Ahmed S, Siddiqui AK, Rai KR.Low-grade B-cell bronchial associated lymphoid tissue(BALT) lymphoma[J]. Cancer Invest,2002,20(7-8):1059-1068.
[9] Wei S, Li X, Qiu X, et al.Primary lung lymphoma involving the superior vena cava[J]. World J Surg Oncol,2012,10:131.
[10] Hans CP, Weisenburger DD, Greiner TC, et al.Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray[J]. Blood,2004,103(1):275-282.
[11] 陈光祥, 蔡亮, 张伟, 等. 18F-FDG PET/CT 在淋巴瘤结外侵犯中的诊断价值[J]. 放射学实践,2013,28(1):95-98.
[12] Cabanillas F, Rivera N, Pardo WI.Indolent Lymphomas That Present With Clinically Aggressive Features: A Subset of Low-Grade Lymphomas With a Behavior Inconsistent With the Histologic Diagnosis[J]. Clin Lymphoma Myeloma Leuk,2016,16(10):550-557.
[13] 霍真, 李霁, 刘鸿瑞, 等. 北京协和医院对18年间病理诊断肺淋巴瘤患者的回顾分析[J]. 中华肺部疾病杂志,2016,9(6):600-603.
[14] 关炜, 王全师, 吴湖炳, 等. 原发性肠淋巴瘤的18F-FDG PET/CT影像学表现[J]. 南方医科大学学报,2016,36(9):1175-1180.
[15] Tamayo P, Martín A, Díaz L, et al.18F-FDG PET/CT in the clinical management of patients with lymphoma[J]. Rev Esp Med Nucl Imagen Mol,2017,36(5):312-321.
[16] Saillard C, Guermouche H, Derrieux C, et al.Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma[J]. Hematol Oncol,2017,35(4):864-868.
[17] Grignano E, Mekinian A, Braun T, et al.Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and litera-ture review[J]. Leuk Res,2016,47:136-141.
[18] Mathew RA, Bennett JM, Liu JJ, et al.Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature[J]. Leuk Res,2012,36(1):72-80.
[19] 王媛媛, 沈金辉, 王少洪. 传染性单核细胞增多症淋巴结病临床病理观察[J]. 诊断病理学杂志,2015,22(10):614-616.
[20] Toriihara A, Nakajima R, Arai A, et al.Pathogenesis and FDG-PET/CT findings of Epstein-Barr virus-related lymphoid neoplasms[J]. Ann Nucl Med,2017,31(6):425-436.
[21] 于亚平, 宋萍, 安志明, 等. 成人非典型传染性单核细胞增多症临床病理特点[J]. 中国实验血液学杂志,2016,24(6):1873-1878.
